» Articles » PMID: 28629526

Erythropoietin Receptor Signaling and Lipid Rafts

Overview
Journal Vitam Horm
Date 2017 Jun 21
PMID 28629526
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Erythropoiesis is tightly regulated by the growth factor erythropoietin (Epo). Signal activation begins when Epo engages its cognate receptor, Epo-R, triggering receptor homodimerization, and recruitment of signaling intermediates including Jak2 that phosphorylates both the receptor cytoplasmic tail and downstream effectors including the transcription factor, STAT5. Transcription factors subsequently activate transcription of prosurvival and prodifferentiation genes responsible for red blood cell production. The fidelity of Epo-R signaling is dependent upon residence within detergent insoluble membrane lipid raft fractions. Lipid rafts are membrane microdomains that serve as signaling scaffolds composed of densely packed sphingolipids and cholesterol where receptors and intermediate signaling proteins are recruited and interact to execute stimuli. Disruption of lipid rafts is detrimental to Epo signaling, a phenomenon that may be utilized to design novel therapeutics for conditions in which Epo signaling is deficient. Here, we review the Epo signaling cascade, particularly, as it relates to localization and dependence on lipid rafts, and discuss considerations for novel therapeutic design.

Citing Articles

The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.

Lin T, Lai Y, Chen Y, Lu D Int J Mol Sci. 2022; 23(24).

PMID: 36555679 PMC: 9784015. DOI: 10.3390/ijms232416038.


Neurological recovery and antioxidant effect of erythropoietin for spinal cord injury: A systematic review and meta-analysis.

Zhang Y, Yao M, Zhu K, Xue R, Xu J, Cui X Front Neurol. 2022; 13:925696.

PMID: 35928137 PMC: 9343731. DOI: 10.3389/fneur.2022.925696.


Effects of PHD and HSP90 on erythropoietin production in yak (Bos grunniens) renal interstitial fibroblast-like cells under hypoxia.

Cui Y, Li H, Yu S, Afedo S, Bai X J Mol Histol. 2022; 53(2):395-411.

PMID: 35084636 DOI: 10.1007/s10735-021-10054-6.


Plasma Ceramides Pathophysiology, Measurements, Challenges, and Opportunities.

Gaggini M, Pingitore A, Vassalle C Metabolites. 2021; 11(11).

PMID: 34822377 PMC: 8622894. DOI: 10.3390/metabo11110719.


Genome Wide Assessment of Genetic Variation and Population Distinctiveness of the Pig Family in South Africa.

Hlongwane N, Hadebe K, Soma P, Dzomba E, Muchadeyi F Front Genet. 2020; 11:344.

PMID: 32457791 PMC: 7221027. DOI: 10.3389/fgene.2020.00344.


References
1.
Fisher J . Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003; 228(1):1-14. DOI: 10.1177/153537020322800101. View

2.
Ratajczak M, Borkowska S, Mierzejewska K, Kucia M, Mendek-Czajkowska E, Suszynska M . Further evidence that paroxysmal nocturnal haemoglobinuria is a disorder of defective cell membrane lipid rafts. J Cell Mol Med. 2015; 19(9):2193-201. PMC: 4568924. DOI: 10.1111/jcmm.12605. View

3.
Singbartl G . Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig. 1994; 72(6 Suppl):S36-43. View

4.
Mantovani L, Lentini G, Hentschel B, Wickramanayake P, Loeffler M, Diehl V . Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000; 109(2):367-75. DOI: 10.1046/j.1365-2141.2000.02016.x. View

5.
Xu Y, Li J, Ferguson G, Mercurio F, Khambatta G, Morrison L . Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood. 2009; 114(2):338-45. DOI: 10.1182/blood-2009-02-200543. View